<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05095077</url>
  </required_header>
  <id_info>
    <org_study_id>PDE5I-UPR-AAR-01</org_study_id>
    <secondary_id>2020-005839-76</secondary_id>
    <nct_id>NCT05095077</nct_id>
  </id_info>
  <brief_title>Effects of Single Dose Tadalafil on Urethral and Anal Closure Function</brief_title>
  <official_title>Effects of Single Dose Tadalafil on Urethral and Anal Closure Function and on Urinary Flow in Healthy Females: A Randomised, Controlled, Double-blinded, Two-period Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Bispebjerg and Frederiksberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Bispebjerg and Frederiksberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to assess the effect of tadalafil compared to placebo (inactive&#xD;
      comparator) on the urethral - and anal pressure and on urine flow in healthy females.&#xD;
      Further, the purpose of the trial is to evaluate the potential for going forward with studies&#xD;
      of tadalafil in patients suffering from urine or fecal incontinence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Two-period (AB/BA) crossover study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The tadalafil tablets and placebo are over-encapsulated in identical hard-gelatin capsules. The over-encapsulation, packaging and labelling is performed by the hospital pharmacy.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Placebo-corrected change in opening urethral pressure after single dose tadalafil</measure>
    <time_frame>2 hours post-dose</time_frame>
    <description>Difference in average urethral opening pressure (UOP) after administration of 40 mg tadalafil (UOP-tadalafil) compared to UOP after placebo (during relaxation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in average anal opening pressure (AOP) after administration of 40 mg tadalafil compared to AOP after placebo (during relaxation).</measure>
    <time_frame>2-hours post-dose</time_frame>
    <description>Difference in average anal opening pressure (AOP) after administration of 40 mg tadalafil compared to AOP after placebo (during relaxation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in average UOP-tadalafil and average UOP-placebo during squeezing.</measure>
    <time_frame>2-hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in average AOP-tadalafil and average AOP-placebo during squeezing.</measure>
    <time_frame>2-hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elastance (opening/closing) during relaxation and squeezing (tadalafil compared to placebo).</measure>
    <time_frame>2-hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in maximum urine flow rate (Qmax) and average urine flow rate (Qave) after tadalafil and placebo administration, respectively.</measure>
    <time_frame>2-hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Urinary Incontinence,Stress</condition>
  <condition>Fecal Incontinence</condition>
  <arm_group>
    <arm_group_label>Tadalafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are randomized to either 40 mg tadalafil on study day 1 and placebo on study day 2, or placebo on study day 1 and 40 mg tadalafil on study day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects are randomized to either 40 mg tadalafil on study day 1 and placebo on study day 2, or placebo on study day 1 and 40 mg tadalafil on study day 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil 40 MG</intervention_name>
    <description>Single dose on study day 1/2</description>
    <arm_group_label>Tadalafil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical to active IMP</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
          -  Normal weight (Body weight 50 kg or more, Body Mass Index 18-5-30 kg/m2)&#xD;
&#xD;
          -  Sexual abstinence or use of safe contraceptive methods i.e. intrauterine devices,&#xD;
             hormonal contraception (oral contraceptive pills, implants, transdermal patches,&#xD;
             vaginal rings or long acting injections), or surgically sterilized partner throughout&#xD;
             the course of the study and until six days after the study has ended for the subject.&#xD;
             Women who are postmenopausal (defined as no menstrual periods for 12 months or more&#xD;
             prior to enrolment) can be included without use of contraceptive methods.&#xD;
&#xD;
          -  Presentation of a negative urine human chorionic gonadotropin (hCG) urine pregnancy&#xD;
             test prior to dosing (on both study days)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically significant urinary incontinence.&#xD;
&#xD;
          -  Current acute or chronic condition, unless considered clinically irrelevant and stable&#xD;
             by the investigator.&#xD;
&#xD;
          -  Average systolic blood pressure &lt;100 mmHg or &gt;140 mmHg and/or average diastolic blood&#xD;
             pressure &lt;60 mmHg or &gt;90 mmHg (average of three measurements performed at screening).&#xD;
&#xD;
          -  Average pulse &lt; 40 or &gt; 100 beats/minute (average of three measurements performed at&#xD;
             screening).&#xD;
&#xD;
          -  Pregnancy within 6 months before screening and throughout the study period.&#xD;
&#xD;
          -  Breastfeeding throughout the study period and 6 days after study day 2.&#xD;
&#xD;
          -  Any systemic drug use within 2 weeks before first study drug administration&#xD;
             (prescription drugs, over-the-counter drugs, herbal drugs and illicit drugs), except&#xD;
             for occasional use of paracetamol (up to 4 g/day), hormonal contraceptives and hormone&#xD;
             replacement therapy.&#xD;
&#xD;
          -  Smoking or other regular use of any form of nicotine product during the study period&#xD;
             and the previous 3 months.&#xD;
&#xD;
          -  Alcohol consume 24 hours prior to dosing.&#xD;
&#xD;
          -  Current or prior participation (within 3 months before screening) in other clinical&#xD;
             trials that might affect the results of this study (judged by the investigator).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thea Christoffersen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zelo Phase 1 unit, University Hospital Bispebjerg and Frederiksberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thea Christoffersen, MD</last_name>
    <phone>+4538635102</phone>
    <email>thea.christoffersen@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zelo Phase 1 unit</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thea Christoffersen, MD</last_name>
      <phone>38635201</phone>
      <email>thea.christoffersen@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Bispebjerg and Frederiksberg</investigator_affiliation>
    <investigator_full_name>Thea Christoffersen</investigator_full_name>
    <investigator_title>Medical Doctor, Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fecal Incontinence</mesh_term>
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

